SynthesisThe Cochrane database of systematic reviews2020
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Synthesis in The Cochrane database of systematic reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 11 syntheses or guidelines pooled it.
- Early drug treatment in preterm patients with large patent ductus arteriosus at 28 weeks or less gestational age: systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2025Pooled it
- Pooled it
- European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update.Neonatology · 2023Guideline
- Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.The Cochrane database of systematic reviews · 2022Pooled it
- Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2022Pooled it
- Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in preterm infants: a network meta-analysis.The Cochrane database of systematic reviews · 2022Pooled it
- Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants.Paediatric drugs · 2022Pooled it
- Indomethacin for symptomatic patent ductus arteriosus in preterm infants.The Cochrane database of systematic reviews · 2021Pooled it
- Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.The Cochrane database of systematic reviews · 2020Pooled it
- Enteral feeding during cyclooxygenase inhibitor treatment for patent ductus arteriosus: A systematic review.Pediatrics international : official journal of the Japan Pediatric SocietyPooled it
- Furosemide for patent ductus arteriosus during cyclooxygenase inhibitor therapy: A systematic review.Pediatrics international : official journal of the Japan Pediatric SocietyPooled it
- Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen.The New England journal of medicine · 2024Trial
- A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants.Journal of perinatology : official journal of the California Perinatal Association · 2021Trial
- Effectiveness and safety of rectal dexibuprofen versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants with gestational age<34 weeks: A pilot study.International journal of immunopathology and pharmacologyTrial
- PDA Treatment Strategy and Pulmonary Hemorrhage Risk in Very Low Birth Weight Infants: A Nationwide Cohort Study.Children (Basel, Switzerland) · 2026Article
- Nutrition of the preterm infant with persistent ductus arteriosus: existing evidence and practical implications.Pediatric research · 2026Review
- Understanding the Impact of Patent Ductus Arteriosus and Treatment Strategies on Acute Kidney Injury in Preterm Infants.American journal of perinatology · 2026Review
- Congenital heart disease prolongs the time to full enteral feeding in neonates with abdominal operation: a dual-center, propensity score-matched retrospective cohort study.Italian journal of pediatrics · 2026Article
- Pharmacologic Therapies for Patent Ductus Arteriosus in Extremely Preterm Infants.JAMA network open · 2026Article
- A Model to Define Reference Ultrasound Parameters for Early Assessment of Nephron Endowment in Extremely Low Birth Weight Preterm Infants.Children (Basel, Switzerland) · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndomethacin is used as standard therapy to close a patent ductus arteriosus (PDA) but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo-oxygenase inhibitor, may be as effective as indomethacin with fewer adverse effects.
objectivesTo determine the effectiveness and safety of ibuprofen compared with indomethacin, other cyclo-oxygenase inhibitor(s), placebo, or no intervention for closing a patent ductus arteriosus in preterm, low-birth-weight, or preterm and low-birth-weight infants. SEARCH
methodsWe used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 10), MEDLINE via PubMed (1966 to 30 November 2017), Embase (1980 to 30 November 2017), and CINAHL (1982 to 30 November 2017). We searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. SELECTION CRITERIA: Randomised or quasi-randomised controlled trials of ibuprofen for the treatment of a PDA in preterm, low birth weight, or both preterm and low-birth-weight newborn infants. DATA COLLECTION AND ANALYSIS: Data collection and analysis conformed to the methods of the Cochrane Neonatal Review Group. We used the GRADE approach to assess the quality of evidence. MAIN
resultsWe included 39 studies enrolling 2843 infants. Ibuprofen (IV) versus placebo: IV Ibuprofen (3 doses) reduced the failure to close a PDA compared with placebo (typical relative risk (RR); 0.62 (95% CI 0.44 to 0.86); typical risk difference (RD); -0.18 (95% CI -0.30 to -0.06); NNTB 6 (95% CI 3 to 17); I AUTHORS'
conclusionsIbuprofen is as effective as indomethacin in closing a PDA. Ibuprofen reduces the risk of NEC and transient renal insufficiency. Therefore, of these two drugs, ibuprofen appears to be the drug of choice. The effectiveness of ibuprofen versus paracetamol is assessed in a separate review. Oro-gastric administration of ibuprofen appears as effective as IV administration. To make further recommendations, studies are needed to assess the effectiveness of high-dose versus standard-dose ibuprofen, early versus expectant administration of ibuprofen, echocardiographically-guided versus standard IV ibuprofen, and continuous infusion versus intermittent boluses of ibuprofen. Studies are lacking evaluating the effect of ibuprofen on longer-term outcomes in infants with PDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.